Brand:
Dragon Pharma, Europe
Manufacturer:
Dragon Pharma, Europe
Dosage Info:
<div class="tab-pane fade" id="offer-tabbody--dosage-and-usage" role="tabpanel">
<section class="tab-panel" id="panel-usage">
<h2>Dosage & Usage Guidelines</h2>
<div class="info-card warning">
<p><strong>For subcutaneous use after reconstitution.</strong> Epitalon is supplied as a lyophilized peptide and must be reconstituted with <a href="/peptides-414/bacteriostatic-water-48726">bacteriostatic water</a> prior to administration.</p>
</div>
<h3>Administration Profile</h3>
<ul class="usage-highlights">
<li>✔ Lyophilized peptide requiring reconstitution</li>
<li>✔ Subcutaneous injection (preferred method)</li>
<li>✔ Short active window, often split into multiple injections</li>
</ul>
<p>After reconstitution, Epitalon is typically administered subcutaneously with rotation of injection sites to minimize irritation. Due to its short activity window, dosing is often divided into multiple administrations per day.</p>
<h3>How is Epitalon 50 mg used?</h3>
<ul>
<li><strong>Standard protocol:</strong> 5–10 mg per day</li>
<li><strong>Administration:</strong> often split into 2 injections (AM / PM)</li>
<li><strong>Cycle duration:</strong> 10–20 consecutive days</li>
</ul>
<p>Epitalon is commonly used in short-duration protocols rather than continuous long-term use.</p>
<h3>Cycle Structure</h3>
<ul>
<li><strong>Duration:</strong> 10–20 days</li>
<li><strong>Frequency:</strong> 2–3 cycles per year</li>
<li><strong>Goal:</strong> longevity-focused or recovery-oriented protocols</li>
</ul>
<p>It is often combined with structured sleep, nutrition, and recovery strategies, and may be included alongside other peptide-based protocols.</p>
<h3>Potential Side Effects</h3>
<ul>
<li>Mild redness or irritation at injection site</li>
<li>Temporary discomfort after administration</li>
<li>Limited long-term human data available</li>
</ul>
<p>Epitalon is generally considered well-tolerated, but due to limited long-term clinical data, individuals with underlying conditions should approach use cautiously.</p>
<h3>Post-Cycle Considerations</h3>
<p>Epitalon does not suppress endogenous hormone production and does not require post-cycle therapy. When used alongside other suppressive compounds, recovery planning should reflect the full protocol.</p>
<div class="info-card">
<p><strong>Important:</strong> Individual response varies. Dosing strategies and overall protocol design should be adjusted based on experience level and tolerance.</p>
</div>
</section>
</div>
Technical Details
Peptide Type
Synthetic Tetrapeptide
Peptide Sequence
Ala-Glu-Asp-Gly (AEDG)
Peptide Length
4 Amino Acids
Chemical Form
Epitalon Monoacetate
Molecular Formula
C₁₆H₂₆N₄O₁₁
Molecular Weight
450.40 g/mol
Parent Peptide
Epitalon (Epithalon)
Development Status
Experimental